Diagnostic Accuracy of CT for Prediction of Bladder Cancer Treatment Response with and without Computerized Decision Support

Publication date: Available online 10 November 2018

Source: Academic Radiology

Author(s): Kenny H. Cha, Lubomir M. Hadjiiski, PhD, Richard H. Cohan, MD, Heang-Ping Chan, PhD, Elaine M. Caoili, MD, Matthew Davenport, MD, Ravi K. Samala, PhD, Alon Z. Weizer, MD, Ajjai Alva, MD, Galina Kirova-Nedyalkova, MD, PhD, Kimberly Shampain, MD, Nathaniel Meyer, MD, Daniel Barkmeier, MD, PhD, Sean Woolen, MD, Prasad R. Shankar, MD, Isaac R. Francis, MD, Phillip Palmbos, MD

Rationale and Objectives

To evaluate whether a computed tomography (CT)-based computerized decision-support system for muscle-invasive bladder cancer treatment response assessment (CDSS-T) can improve identification of patients who have responded completely to neoadjuvant chemotherapy.

Materials and Methods

Following Institutional Review Board approval, pre-chemotherapy and post-chemotherapy CT scans of 123 subjects with 157 muscle-invasive bladder cancer foci were collected retrospectively. CT data were analyzed with a CDSS-T that uses a combination of deep-learning convolutional neural network and radiomic features to distinguish muscle-invasive bladder cancers that have fully responded to neoadjuvant treatment from those that have not. Leave-one-case-out cross-validation was used to minimize overfitting. Five attending abdominal radiologists, four diagnostic radiology residents, two attending oncologists, and one attending urologist estimated the likelihood of pathologic T0 disease (complete response) by viewing paired pre/post-treatment CT scans placed side-by-side on an internally-developed graphical user interface. The observers provided an estimate without use of CDSS-T and then were permitted to revise their estimate after a CDSS-T-derived likelihood score was displayed. Observer estimates were analyzed with multi-reader, multi-case receiver operating characteristic methodology. The area under the curve (AUC) and the statistical significance of the difference were estimated.

Results

The mean AUCs for assessment of pathologic T0 disease were 0.80 for CDSS-T alone, 0.74 for physicians not using CDSS-T, and 0.77 for physicians using CDSS-T. The increase in the physicians' performance was statistically significant (P < .05).

Conclusion

CDSS-T improves physician performance for identifying complete response of muscle-invasive bladder cancer to neoadjuvant chemotherapy.

from Imaging via a.sfakia on Inoreader https://ift.tt/2FhaWHu